- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Matthew Steven Davids, MD, MMSc | Authors
Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s Syndrome
July 26, 2020
The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.
Matthew Steven Davids, MD, MMSc on Venetoclax Plus R-EPOCH in Hematologic Cancers
July 11, 2020
The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.
Venetoclax Plus Dose-Adjusted R-EPOCH Shows Promise for Richter’s Syndrome
June 21, 2020
A multicenter phase 2 study of patients with chronic lymphocytic leukemia who developed Richter’s syndrome, presented at the 2020 ASCO Virtual Scientific Program, assessed the use of this treatment combination.
Matthew Steven Davids, MD, MMSc, Discusses a Phase II Study for Richter’s Syndrome
June 12, 2020
The study evaluated venetoclax plus dose-adjusted R-EPOCH in patients with chronic lymphocytic leukemia who developed Richter’s syndrome.
Matthew Steven Davids, MD, MMSc, on Venetoclax Plus R-EPOCH to Treat Richter’s Syndrome
June 01, 2020
The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter’s Syndrome.